Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
तुलना करने के लिए मीट्रिक्स | 4142 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4142पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −17.0x | −7.2x | −0.6x | |
PEG अनुपात | −1.05 | 0.34 | 0.00 | |
क़ीमत/बुक | 1.8x | 3.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 7.2x | 4.1x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 61.2% | 41.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 2.7% | 5.5% | अनलॉक करें |